论文部分内容阅读
目的探讨拉米夫定治疗肺结核合并慢性乙肝的临床疗效。方法将128例肺结核合并慢乙肝患者随机分为对照组与观察组,对照组患者接受常规抗结核及护肝治疗,观察组患者同时接受拉米夫定口服治疗。治疗3个月后评估2组的疗效。结果观察组患者痰菌阴转率及病灶显吸率显著优于对照组(P<0.05);观察组患者肝功能损伤发生率显著低于对照组(P<0.05);与对照组比较,观察组肝功能指标ALT、AST、TBIL及乙肝病毒复制指标HBV-DNA水平显著降低(P<0.05)。结论拉米夫定治疗肺结核合并慢乙肝疗效显著,可显著减少肝功能损害,并快速抑制乙肝病毒复制。
Objective To investigate the clinical efficacy of lamivudine in the treatment of pulmonary tuberculosis complicated with chronic hepatitis B Methods 128 cases of tuberculosis with chronic hepatitis B were randomly divided into control group and observation group. Patients in control group received routine anti-tuberculosis and hepatoprotective therapy. Patients in observation group received lamivudine oral treatment at the same time. The efficacy of the two groups was evaluated after 3 months of treatment. Results The sputum negative conversion rate and the apparent suction rate in the observation group were significantly better than those in the control group (P <0.05). The incidence of hepatic injury in the observation group was significantly lower than that in the control group (P <0.05). Compared with the control group, Group of liver function indicators ALT, AST, TBIL and hepatitis B virus replication indicators HBV-DNA levels were significantly lower (P <0.05). Conclusion Lamivudine treatment of tuberculosis with chronic hepatitis B significantly, can significantly reduce liver damage, and rapid inhibition of hepatitis B virus replication.